Top

Published in:

01-07-2020 | Bisphosphonate | Viewpoints

Osteoporosis in the age of COVID-19

Authors: C. M. Girgis, R. J. Clifton-Bligh

Published in: Osteoporosis International | Issue 7/2020

Abstract

As the world grapples with the crisis of COVID-19, established economies and healthcare systems have been brought to their knees. Tough decisions regarding redirection of resources away from the management of conditions deemed “nonessential” are being made. How can we balance urgent resourcing of our acute crisis while not abandoning the real need of patients with osteoporosis? This article offers a few practical solutions.

Hollander JE, Carr BG (2020) Virtually perfect? Telemedicine for Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMp2003539

Schnell S, Friedman SM, Mendelson DA, Bingham KW, Kates SL (2010) The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil 1(1):6–14CrossRef

Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733CrossRef

Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15(11):897–902CrossRef

Binkley N, Blank RD, Leslie WD, Lewiecki EM, Eisman JA, Bilezikian JP (2017) Osteoporosis in crisis: It’s time to focus on fracture. J Bone Miner Res 32(7):1391–1394CrossRef

Black DM, Rosen CJ (2016) Postmenopausal osteoporosis. N Engl J Med 374(21):2096–2097PubMed

Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30(1):79–92CrossRef

Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD, McCloskey EV (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32(2):187–196CrossRef

Ahmed LA, Nguyen ND, Bjornerem A, Joakimsen RM, Jorgensen L, Stormer J et al (2014) External validation of the Garvan nomograms for predicting absolute fracture risk: the Tromso study. PLoS One 9(9):e107695CrossRef

10.

Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K (2017) Factors associated with acute-phase response of bisphosphonate-naive or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int 28(6):1995–2002CrossRef

11.

Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F et al (2018) Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin D and previous Oral bisphosphonate therapy. Endocr Pract 24(5):405–410CrossRef

12.

Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32(6):1291–1296CrossRef

13.

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 105:11–17CrossRef

14.

Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E et al (2019) Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 30(9):1733–1743CrossRef

15.

Barrionuevo P, Gionfriddo MR, Castaneda-Guarderas A, Zeballos-Palacios C, Bora P, Mohammed K, Benkhadra K, Sarigianni M, Murad MH (2019) Women’s values and preferences regarding osteoporosis treatments: a systematic review. J Clin Endocrinol Metab 104(5):1631–1636CrossRef

16.

Nanduri AP, Fullman S, Morell L, Buyske S, Wagner ML (2018) Pilot study for implementing an osteoporosis education and exercise program in an assisted living facility and senior community. J Appl Gerontol 37(6):745–762CrossRef

17.

Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR (2018) High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res 33(2):211–220CrossRef

18.

Papaioannou A, Adachi JD, Winegard K, Ferko N, Parkinson W, Cook RJ, Webber C, McCartney N (2003) Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int 14(8):677–682CrossRef

Title: Osteoporosis in the age of COVID-19
Authors: C. M. Girgis
R. J. Clifton-Bligh
Publication date: 01-07-2020
Publisher: Springer London
Keywords: Bisphosphonate
Osteoporosis
COVID-19
Osteoporosis
Denosumab
Denosumab
Published in: Osteoporosis International / Issue 7/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-020-05413-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Osteoporosis in the age of COVID-19

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2020

Incidence of fractures in patients with type 1 diabetes mellitus—a retrospective study with 4420 patients

Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia

A systematic review of the indirect and social costs studies in fragility fractures

Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017

Anorexia Nervosa with Markedly High Bone Turnover and Hyperphosphatemia During Refeeding Rectified by Denosumab

Hip fractures and characteristics of living area: a fine-scale spatial analysis in France